secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001599298-24-000156
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit reports Q3 net loss $56.3M; ivonescimab HARMONi-2 shows 49% risk reduction vs Keytruda
--------------------------------------------------------------------------------

- Cash and short-term investments $487M (vs $186.2M Dec 2023) after $235M private financing in Sep 2024.
- GAAP net loss $56.3M ($0.08/share) vs $21.2M ($0.03/share) in Q3 2023; R&D spend $37.7M.
- Ivonescimab in HARMONi-2 (NSCLC) reduced disease progression/death by 49% vs pembrolizumab (HR 0.51; p<0.0001).
- HARMONi (2L+ EGFRm) enrollment complete; topline mid-2025. HARMONi-3 to expand to non-squamous; HARMONi-7 to start early 2025.
- Phase II data at ESMO/WCLC showed 71.8% MPR in perioperative NSCLC, 84.6% ORR in MSS CRC, 72.4% ORR in TNBC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000156/0001599298-24-000156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000156/smmt-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer